Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
European Viper Venom Antiserum
- Development stage
- Preclinical
- Lead developer
- Institute of Immunology
- Modality
- Antibody-Based Therapeutics
- Administration
- Intravenous, Intramuscular
01
Overview
European Viper Venom Antiserum is an equine-derived polyvalent biological product developed by the Institute of Immunology (IMZ) in Zagreb for the treatment of snake envenomation. It is specifically designed to neutralize the venoms of several medically significant European vipers, including the nose-horned viper (*Vipera ammodytes*), common adder (*Vipera berus*), asp viper (*Vipera aspis*), Ottoman viper (*Vipera xanthina*), and Levantine viper (*Vipera lebetina*). The antiserum contains polyclonal antibodies, typically purified as F(ab')2 fragments from the plasma of horses immunized with these specific venoms. These antibodies work by binding to and neutralizing various toxic components within the venom, such as phospholipases A2 and proteases, thereby preventing systemic toxicity and local tissue damage. The program is currently in a preclinical phase aimed at revitalizing manufacturing processes to ensure the continued availability of this essential therapeutic.
- Other names
- European Viper Venom Antiserum (Equine)Equine polyvalent antivenom
02
Targets
Atx (Phospholipase A2 neurotoxin ammodytoxin)Vipera aspis venom toxinsSVSP (Snake venom serine protease)SVMP (Snake venom metalloproteinase)
Beyond the preview
Go deeper on European Viper Venom Antiserum.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on European Viper Venom Antiserum.